| Company | Date | Position | Consensus β | Price Target β | 1-Yr Return | vs S&P 500 β |
|---|---|---|---|---|---|---|
|
PHAT
Phathom Pharmaceuticals
|
Oct 30, 2026 | BUY |
Strong Buy
+316.6% avg upside
15 analysts
|
$14.00
144.00% Upside
|
-8.5% | Β· |
|
COLL
Collegium Pharmaceutical
|
Oct 15, 2026 | BUY |
Strong Buy
+77.4% avg upside
10 analysts
|
$48.00
101.62% Upside
|
+2.1% | Β· |
|
TARS
Tarsus Pharmaceuticals
|
Oct 09, 2026 | BUY |
Strong Buy
+9.9% avg upside
17 analysts
|
$110.00
47.00% Upside
|
+1.7% | Β· |
|
XERS
Xeris Pharmaceuticals
|
Oct 06, 2026 | BUY |
Strong Buy
+3.9% avg upside
10 analysts
|
$14.00
30.66% Upside
|
+7.7% | Β· |
|
PCRX
Pacira Pharmaceuticals
|
Aug 17, 2026 | HOLD |
Hold
+11.8% avg upside
23 analysts
|
$25.00
31.37% Downside
|
+56.7% | Β· |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.